

Applicant : Ilya Trakht et al.
Serial No.: 09/664,958
Filed: September 18, 2000
Page 11

Amendments to the Claims:

Please cancel claims 1-5, 8 and 10-15 without disclaimer or prejudice to applicants' right to pursue the subject matter of these claims at a later date in a continuing application.

Please also add new claims 175-184.

In accordance with revised 37 C.F.R. §1.121, please amend claims 6, 9, 16 and 18 as indicated below.

The text of all claims under examination is provided below, with deleted matter indicated by strikethrough and added matter indicated by underlining. These markings have been made only in claims being currently amended.

Claims

1-5. (Cancelled)

6. (Currently Amended) The A monoclonal antibody of claim 1 which specifically binds and forms a complex with TIP-2 antigen located on the surface of human cancer cells, wherein the monoclonal antibody binds to the same extracellular domain of TIP-2 as does monoclonal antibody 27.B1 produced by hybridoma 27.B1 (ATCC Designation No. PTA-1599).

7. (Original): The monoclonal antibody 27.B1 produced by hybridoma 27.B1 (ATCC Designation No. PTA-1599).

8. (Cancelled)

Applicant : Ilya Trakht et al.
Serial No.: 09/664,958
Filed: September 18, 2000
Page 12

9. (Currently Amended): The hybridoma ~~of claim 8~~ cell designated 27.B1 (ATCC Accession No. PTA-1599).

10-15. (Cancelled)

16. (Currently Amended) ~~The~~ A monoclonal antibody ~~of claim 1~~ which specifically binds and forms a complex with TIP-2 antigen located on the surface of human cancer cells, wherein the monoclonal antibody binds to the same extracellular domain of TIP-2 as does monoclonal antibody 27.F7 produced by hybridoma 27.F7 (ATCC Designation No. PTA-1598).

17. (Original): The monoclonal antibody 27.F7 produced by hybridoma 27.F7 (ATCC Designation No. 1598).

18. (Currently Amended): The hybridoma ~~of claim 8~~ cell designated 27.F7 (ATCC Accession No. PTA-1598).

19-174. (Cancelled)

175. (New) A kit for detecting the presence of TIP-2 antigen-bearing cancer cells in a sample comprising:

- a) a solid support having a plurality of immobilized probes which may be the same or different, wherein each probe comprises a monoclonal antibody or Fab fragment thereof which specifically binds and forms a complex with TIP-2 antigen located on the surface of human cancer cells; and
- b) a means for determining the presence of the probe/TIP-2 antigen complex.

Applicant : Ilya Trakht et al.
Serial No.: 09/664,958
Filed: September 18, 2000
Page 13

176. (New) The kit of claim 175, wherein the probe binds to the same TIP-2 domain as does monoclonal antibody 27.B1 produced by hybridoma 27.B1 (ATCC Designation No. PTA-1599) or as does monoclonal antibody 27.F7 produced by hybridoma 27.F7 (ATCC Designation No. PTA-1598).
177. (New) The kit of claim 176, wherein the probe is a murine monoclonal antibody.
178. (New) The kit of claim 176, wherein the probe is a chimeric monoclonal antibody.
179. (New) The kit of claim 176, wherein the probe is a humanized monoclonal antibody.
180. (New) The kit of claim 176, wherein the probe is a human monoclonal antibody.
181. (New) The kit of claim 176, wherein the probe is human monoclonal antibody 27.B1 produced by hybridoma 27.B1 (ATCC Designation No. PTA-1599) or human monoclonal antibody 27.F7 produced by hybridoma 27.F7 (ATCC Designation No. PTA-1598).
182. (New) The kit of claim 176, wherein the means for determining the presence of the probe/TIP-2 antigen complex comprises a detectably labeled antibody.
183. (New) The kit of claim 176, wherein the means for determining the presence of the probe/TIP-2 antigen complex comprises a detectably labeled antibody which

Applicant : Ilya Trakht et al.
Serial No.: 09/664,958
Filed: September 18, 2000
Page 14

specifically binds to a monoclonal antibody directed to TIP-2 antigen.

184. (New) The kit of claim 182 or 183, wherein the detectable label is a radioactive isotope, enzyme, dye, biotin, fluorescent label or chemiluminescent label.